ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.002,02
-1,43%
S&P 500
5.431,60
-0,04%
Dow Jones
38.589,16
-0,15%
Euro vs US Dollar
1,07175
-0,05%
Bitcoin
66.200,00
0,29%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. DiaMedica Therapeutics Inc (DMAC)

  7. DiaMedica Therapeutics Inc (DMAC) News

DMAC

DiaMedica Therapeutics (DMAC)

DiaMedica Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:DMAC
DatumZeitQuelleÜberschriftSymbolFirma
03/06/202423h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DMACDiaMedica Therapeutics Inc
03/06/202422h59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DMACDiaMedica Therapeutics Inc
03/06/202422h58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DMACDiaMedica Therapeutics Inc
03/06/202422h41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DMACDiaMedica Therapeutics Inc
03/06/202422h35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DMACDiaMedica Therapeutics Inc
03/06/202422h29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DMACDiaMedica Therapeutics Inc
03/06/202422h21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DMACDiaMedica Therapeutics Inc
03/06/202422h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DMACDiaMedica Therapeutics Inc
03/06/202422h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DMACDiaMedica Therapeutics Inc
24/05/202422h01Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:DMACDiaMedica Therapeutics Inc
23/05/202422h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DMACDiaMedica Therapeutics Inc
08/05/202422h34Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DMACDiaMedica Therapeutics Inc
08/05/202422h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DMACDiaMedica Therapeutics Inc
08/05/202422h30Business WireDiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial ResultsNASDAQ:DMACDiaMedica Therapeutics Inc
02/05/202414h55Business WireDiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024NASDAQ:DMACDiaMedica Therapeutics Inc
17/04/202422h08Business WireDiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic StrokeNASDAQ:DMACDiaMedica Therapeutics Inc
19/03/202421h15Business WireDiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial ResultsNASDAQ:DMACDiaMedica Therapeutics Inc
29/01/202422h13Business WireDiaMedica Therapeutics Announces Poster Presentation at International Stroke ConferenceNASDAQ:DMACDiaMedica Therapeutics Inc
23/01/202422h23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DMACDiaMedica Therapeutics Inc
23/01/202422h12Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:DMACDiaMedica Therapeutics Inc
22/01/202414h23Business WireDiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical OfficerNASDAQ:DMACDiaMedica Therapeutics Inc
02/01/202423h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DMACDiaMedica Therapeutics Inc
02/01/202422h47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DMACDiaMedica Therapeutics Inc
02/01/202422h39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DMACDiaMedica Therapeutics Inc
02/01/202422h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DMACDiaMedica Therapeutics Inc
16/11/202322h37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DMACDiaMedica Therapeutics Inc
13/11/202322h55Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DMACDiaMedica Therapeutics Inc
13/11/202322h52Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DMACDiaMedica Therapeutics Inc
13/11/202322h28Business WireDiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial ResultsNASDAQ:DMACDiaMedica Therapeutics Inc
09/11/202314h25Business WireDiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023NASDAQ:DMACDiaMedica Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:DMAC

Kürzlich von Ihnen besucht

ASX
AMPBOI
LSE
16AW
Investec Bnk 24
DBI
I2HF
INAV XTRACKERS MSCI CHIN...
BIT
P20P45
NLBNPIT20P45 20991231 12...
BIT
F17169
Vontobel Financial Produ...
FX
MXVMXN
MXV vs MXN
TSXV
MEEC
Midwest Energy Emissions
LATK
SEGUSDT
Solar Energy
TSX
PPL.PF.A
Pembina Pipeline
NASDAQ
OPXAW
USOTC
TDGMW
Tidewater (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten